个人简介：

Dr. Song is a physician-scientist-turned entrepreneur and is the co-founder of Kira Therapeutics, a new biotech startup based on cutting-edge immunological sciences. Dr. Song was most recently as the global VP and global clinical leader of Immuno-Oncology development at AstraZeneca Global Medicines Development where he initially led the Asia Pacific immune-oncology (IO) development and later led the global program for IO combinations and IO new indications. Previously, Dr. Song was the Head of Regional Oncology Development in Asia-Pacific at Millennium: The Takeda Oncology Company where he had led the building of Takeda’s regional oncology development infrastructure and oncology clinical development. Prior to joining Millennium, Dr. Song was a medical director/clinical lead at Pfizer Oncology where he led a number of cancer immunotherapy and antibody-drug conjugate (ADC) programs. Before joining the pharma-industry in 2008, he was an associate investigator at Baylor Institute of Immunology Research and an attending oncologist at Baylor Sammons Cancer Center in Dallas. He studied Medicine at Shandong University in China before coming to the US for his PhD study in Immunology. He then did a postdoctoral fellowship in cancer immunotherapy with Dr. Ron Crystal at Cornell University Medical Center, followed by medical residency training at Montefiore Medical Center/Albert Einstein College of Medicine, and clinical oncology fellowship at Stanford University where he also performed research on cancer immunotherapy with Drs. Ron Levy and Ed Engleman.

Dr. Song has a long-time track record in translational and clinical research in cancer immunotherapy. He was the first to demonstrate that genetically modified dendritic cells (DCs) expressing tumor antigens could serve as effective therapeutic cancer vaccines (J Exp Med 1997). He was also among the first to manipulate tumor microenvironment for in-situ tumor vaccination (Can Res 2001 &2005; J Immunol 2007). With the approval of three investigator-initiated IND applications from the US FDA, he started to translate his lab research in cancer immunotherapy by initiating phase I/II clinical trials in patients with colon or pancreatic cancer at Stanford University and in patients with lymphoma at Baylor Sammons Cancer Center. Dr. Song has also contributed to the global immune biomarker expert taskforce efforts (Clin Can Res 2011; J Immunotherapy Can 2016). His academic and industry working experience (with immune modulators, vaccine, and ADC in both early and late stage studies) has allowed him to gain extensive and broad expertise in translational and clinical research and in drug development for a variety of hematological and solid tumors.

Dr. Song has actively participated in community services and professional organizations. He is a founding board member, past Board Chair and the past-president of the Chinese American Hematologist and Oncologist Network, a former member of the Ad Hoc Committee on International Outreach of the American Society of Hematology (ASH), a former member of Career Development Committee of the American Society of Clinical Oncology (ASCO), a former member of the NCI's Immune Response Modifier Pathway Prioritization Working Group. He currently serves as an overseas member of the Executive Committee of the Chinese Society of Clinical Oncology, a member of the Industry Council and Immune Biomarker Taskforce of the Society for Immunotherapy of Cancer, and most recently a member of ASH Foundation Committee and a member of the International Affairs Committee of ASCO. Dr. Song serves in the Editorial Board of Journal of Hematology and Oncology and Chinese Clinical Oncology.